VX-668 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Alpha-1 Antitrypsin Deficiency
Conditions
Alpha-1 Antitrypsin Deficiency
Trial Timeline
Feb 8, 2023 → Feb 13, 2024
NCT ID
NCT05727800About VX-668 + Placebo
VX-668 + Placebo is a phase 1 stage product being developed by Vertex Pharmaceuticals for Alpha-1 Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT05727800. Target conditions include Alpha-1 Antitrypsin Deficiency.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05727800 | Phase 1 | Completed |
Competing Products
13 competing products in Alpha-1 Antitrypsin Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) Placebo | Novartis | Phase 2 | 52 |
| VX-864 | Vertex Pharmaceuticals | Phase 2 | 51 |
| ALN-AAT02 + Placebo + ALN-AAT02 | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| ARC-AAT Injection + Diphenhydramine | Arrowhead Pharmaceuticals | Phase 1 | 30 |
| ARC-AAT Injection | Arrowhead Pharmaceuticals | Phase 2 | 49 |
| Alpha-1 MP | Grifols | Phase 3 | 74 |
| Alpha-1 MP | Grifols | Phase 3 | 74 |
| WVE-006 | WaVe Life Sciences | Phase 1 | 28 |
| WVE-006 | WaVe Life Sciences | Phase 1/2 | 36 |
| INBRX-101/rhAAT-Fc | Inhibrx Biosciences | Phase 1 | 28 |
| Kamada-AAT for Inhalation, 80mg + Placebo + Kamada-AAT for Inhalation, 160mg | Kamada | Phase 2 | 44 |
| KRRO-110 | Korro Bio | Phase 1/2 | 33 |
| Alvelestat (MPH966) | Mereo BioPharma | Phase 2 | 44 |